Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026

- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - BBT002 demonstrated rapid, deep, and sustained biomarker effects through at least 8 weeks following multiple doses, consistent with the SAD data, with a ~29.4-day half-life supporting extended dosing intervals - - Topline data from ongoing proof-of-concept trials evaluating BBT002 in patients with COPD and CRSwNP anticipated by year-end 2026 and first ha